A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients with Recurrent/progressive High-grade Glioma.

BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.